Risk of allergic rhinitis in patients with inflammatory bowel disease: A systematic review and meta-analysis
Main Article Content
Keywords
allergic rhinitis, inflammatory bowel disease, meta-analysis
Abstract
Background: Numerous parallels exist between inflammatory bowel disease (IBD) and allergic rhinitis (AR), which include risk factors (such as environmental and genetic factors), pathogenesis (immune disorders, epithelial cell barriers, etc.), and treatment (immunosuppressants and immunomodulators, such as cyclosporine and steroids). However, the risk of AR in IBD patients is unknown.
Objective: In this systematic review and meta-analysis, patients with IBD are examined for their risk of AR.
Methods: Several databases are accessible in both Chinese and English, including PubMed, BioRXiv, WanFang, the China National Knowledge Infrastructure (CNKI), Web of Science, METSTR, and MedRxiv. Findings presented at allergy, rhinology, thoracic, and gastrointestinal conferences were analyzed. Based on the inclusion and exclusion criteria, two evaluators independently retrieved data, read the literature, and evaluated bias risk. The data analysis was conducted using RevMan 5.4. Case-control and cohort studies were eligible study designs for this research.
Results: There were 10 case-control studies and 1 cohort study included in the meta-analysis. The experimental group consisted of 65,687 IBD patients, of whom 5838 had AR. A total of 345,176 participants without IBD were included in the control group, of whom 24,625 developed AR. The outcomes demonstrated that IBD patients had a higher risk of developing AR (odds ratio [OR] = 1.48, 95% confidence interval [CI] [1.12, 1.95], Z = 2.78, P = 0.005) than those without IBD.
Conclusion: The risk of AR is higher in IBD patients. Further investigation is required to determine the mechanism behind the association between AR and IBD.
References
1. Hellings PW, Fokkens WJ. Allergic rhinitis and its impact on otorhinolaryngology. Allergy. 2006;61(6):656–64. 10.1111/j.1398-9995.2006.01109.x
2. Izquierdo-Domínguez A, Valero AL, Mullol J. Comparative analysis of allergic rhinitis in children and adults. Curr Allergy Asthma Rep. 2013;13(2):142–51. 10.1007/s11882-012-0331-y
3. Asher MI, Montefort S, Björkstén B, Lai CKW, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43. 10.1016/S0140-6736(06)69283-0
4. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005;60(3):350–3. 10.1111/j.1398-9995.2005.00751.x
5. Cardell L-O, Olsson P, Andersson M, Welin K-O, Svensson J, Tennvall GR, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. 10.1038/npjpcrm.2015.82
6. Testa D, Di Bari M, Nunziata M, Cristofaro GDE, Massaro G, Marcuccio G, et al. Allergic rhinitis and asthma assessment of risk factors in pediatric patients: A systematic review. Int J Pediatr Otorhinolaryngol. 2020;129:109759. 10.1016/j.ijporl.2019.109759
7. Asher MI, Stewart AW, Mallol J, Montefort S, Lai CKW, Aït-Khaled N, et al. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respir Res. 2010;11(1):8. 10.1186/1465-9921-11-8
8. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161(10):5733–44. 10.4049/jimmunol.161.10.5733
9. Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329(20):1468–75. 10.1056/NEJM199311113292007
10. Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory bowel disease. Dtsch Arztebl Int. 2016;113(5):72–82. 10.3238/arztebl.2016.0072
11. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053–60. 10.1001/jamapediatrics.2015.1982
12. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133(2):291–307. 10.1016/j.jaci.2013.11.020
13. Ko JK, Auyeung KK. Inflammatory bowel disease: Etiology, pathogenesis and current therapy. Curr Pharm Des. 2014;20(7):1082–96. 10.2174/13816128113199990416
14. Bernstein DI, Schwartz G, Bernstein JA. Allergic rhinitis: Mechanisms and treatment. Immunol Allergy Clin North Am. 2016;36(2):261–78. 10.1016/j.iac.2015.12.004
15. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–61. 10.1097/MPG.0b013e3182662233
16. Lee J W, Eun C S. Inflammatory bowel disease in Korea: Epidemiology and pathophysiology. Korean J Intern Med. 2022; 37(5):885–94. 10.3904/kjim.2022.138
17. Wasielewska Z, Dolinska A, Wilczynska D, Szaflarska-Poplawska A, Krogulska A. Prevalence of allergic diseases in children with inflammatory bowel disease. Postepy Dermatol Alergol. 2019;36(3):282–90. 10.5114/ada.2018.81189
18. Tzanakis NE, Tsiligianni IG, Siafakas NM. Pulmonary involvement and allergic disorders in inflammatory bowel disease. World J Gastroenterol. 2010;16(3):299–305. 10.3748/wjg.v16.i3.299
19. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–31. 10.3748/wjg.v12.i30.4819
20. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84. 10.7326/M14-2385
21. Wells G A, Wells G, Shea B, Shea B, O’Connell D, Peterson J, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, F, 2014 [C].
22. Alenezy N, Nugent Z, Herman S, Zaborniak K, Ramsey CD, Bernstein CN. Aeroallergen-related diseases predate the diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2023;29(7):1073–9. 10.1093/ibd/izac184
23. Card TR, Langan SM, Chu TP. Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported. Dig Dis Sci. 2016;61(9):2619–26. 10.1007/s10620-016-4195-1
24. Kappelman MD, Galanko JA, Porter CQ, Sandler RS. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child. 2011;96(11):1042–6. 10.1136/archdischild-2011-300633
25. Radon K, Windstetter D, Poluda AL, Mueller B, von Mutius E, Koletzko S. Contact with farm animals in early life and juvenile inflammatory bowel disease: A case-control study. Pediatrics. 2007;120(2):354–61. 10.1542/peds.2006-3624
26. Myrelid P, Dufmats M, Lilja I, Grinn C, Lannerstad O, Sjödahl R. Atopic manifestations are more common in patients with Crohn disease than in the general population. Scand J Gastroenterol. 2004;39(8):731–6. 10.1080/00365520410005955
27. D’Arienzo A, Manguso F, Scarpa R, Astarita C, D’Armiento FP, Bennato R, et al. Ulcerative colitis, seronegative spondyloarthropathies and allergic diseases: The search for a lin. Scand J Gastroenterol. 2002;37(10):1156–63. 10.1080/003655202760373362
28. D’Arienzo A, Manguso F, Astarita C, D’Armiento FP, Scarpa R, Gargano D, et al. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol. 2000;35(6):624–31. 10.1080/003655200750023598
29. Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. Front Microbiol. 2018;9:1459. 10.3389/fmicb.2018.01459
30. Pugh SM, Rhodes J, Mayberry JF, Roberts DL, Heatley RV, Newcombe RG. Atopic disease in ulcerative colitis and Crohn’s disease. Clin Allergy. 1979;9(3):221–3. 10.1111/j.1365-2222.1979.tb01545.x
31. Jewell DP, Truelove SC. Reaginic hypersensitivity in ulcerative colitis. Gut. 1972;13(11):903–6. 10.1136/gut.13.11.903
32. Hammer B, Ashurst P, Naish J. Diseases associated with ulcerative colitis and Crohn’s disease. Gut. 1968;9(1):17–21. 10.1136/gut.9.1.17
33. Dixon LJ, Kabi A, Nickerson KP, McDonald C. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2015;21(4):912–22. 10.1097/MIB.0000000000000289
34. Guo AY, Stevens BW, Wilson RG, Russell CN, Cohen MA, Sturgeon HC, et al. Early life environment and natural history of inflammatory bowel diseases. BMC Gastroenterol. 2014;14:216. 10.1186/s12876-014-0216-8
35. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25(2):325–33. 10.1111/j.1440-1746.2009.06140.x
36. Garn H, Bahn S, Baune BT, Binder EB, Bisgaard H, Chatila TA, et al. Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation. J Allergy Clin Immunol. 2016;138(1):47–56. 10.1016/j.jaci.2016.02.046
37. Li M, Wang M, Donovan SM. Early development of the gut microbiome and immune-mediated childhood disorders. Semin Reprod Med. 2014;32(1):74–86. 10.1055/s-0033-1361825
38. Nur Husna SM, Tan H-TT, Md Shukri N, Mohd Ashari NS, Wong KK. Nasal epithelial barrier integrity and tight junctions disruption in allergic rhinitis: Overview and pathogenic insights. Front Immunol. 2021;12:663626. 10.3389/fimmu.2021.663626
39. Zhang R, Zhang L, Li P, Pang K, Liu H, Tian L. Epithelial barrier in the nasal mucosa, related risk factors and diseases. Int Arch Allergy Immunol. 2023;184(5):481–501. 10.1159/000528969
40. Vancamelbeke M, Vermeire S. The intestinal barrier: A fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821–34. 10.1080/17474124.2017.1343143
41. Salvo Romero E, Alonso Cotoner C, Pardo Camacho C, Casado Bedmar M, Vicario M. The intestinal barrier function and its involvement in digestive disease. Rev Esp Enferm Dig. 2015;107(11):686–96. 10.17235/reed.2015.3846/2015
42. Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, et al. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Front Nutr. 2021;8:718356. 10.3389/fnut.2021.718356
43. Vutcovici M, Brassard P, Bitton A. Inflammatory bowel disease and airway diseases. World J Gastroenterol. 2016;22(34):7735–41. 10.3748/wjg.v22.i34.7735
44. Einarsson R, Renck B, Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy. 1988;43(6):469–72. 10.1111/j.1398-9995.1988.tb00921.x
45. Kabashima K, Honda T, Ginhoux F, Egawa G. The immunological anatomy of the skin. Nat Rev Immunol. 2019;19(1):19–30. 10.1038/s41577-018-0084-5
46. Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J Leukoc Biol. 2020;107(5):749–62. 10.1002/JLB.5MR0120-230R
47. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33–46. 10.1016/j.jcmgh.2017.03.007
48. Liu X, Tao J, Li J, Cao X, Li Y, Gao X, et al. Dysbiosis of fecal microbiota in allergic rhinitis patients. Am J Rhinol Allergy. 2020;34(5):650–60. 10.1177/1945892420920477
49. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60(5):631–7. 10.1136/gut.2010.223263
50. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813–22. 10.1136/gutjnl-2016-313235
51. Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46(4):479–86. 10.1007/s00535-010-0368-4
52. Lee SY, Lee E, Park YM, Hong SJ. Microbiome in the gut–skin axis in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(4):354–62. 10.4168/aair.2018.10.4.354
53. Virta LJ, Ashorn M, Kolho KL. Cow’s milk allergy, asthma, and pediatric IBD. J Pediatr Gastroenterol Nutr. 2013;56(6):649–51. 10.1097/MPG.0b013e318285e9d8
54. Walker MM, Powell N, Talley NJ. Atopy and the gastrointestinal tract—A review of a common association in unexplained gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8(3):289–99. 10.1586/17474124.2014.881716
55. Kotlyar DS, Shum M, Hsieh J, Blonski W, Greenwald DA. Non-pulmonary allergic diseases and inflammatory bowel disease: A qualitative review. World J Gastroenterol. 2014;20(32):11023–32. 10.3748/wjg.v20.i32.11023
56. Hemdan NY, Birkenmeier G, Wichmann G, Abu El-Saad AM, Krieger T, Conrad K, et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev. 2010;9(11):785–92. 10.1016/j.autrev.2010.07.003
57. Ueno A, Jeffery L, Kobayashi T, Hibi T, Ghosh S, Jijon H. Th17 plasticity and its relevance to inflammatory bowel disease. J Autoimmun. 2018;87:38–49. 10.1016/j.jaut.2017.12.004
58. Liu Y, Zeng M, Liu Z. Th17 response and its regulation in inflammatory upper airway diseases. Clin Exp Allergy. 2015;45(3):602–12. 10.1111/cea.12378
59. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: New immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58(8):1152–67. 10.1136/gut.2008.163667
60. Soh H, Lee HJ, Han K, Park S, Hong SW, Moon JM, et al. Atopic diseases are associated with development of inflammatory bowel diseases in Korea: A nationwide population-based study. Clin Gastroenterol Hepatol. 2021;19(10):2072–2081.e6. 10.1016/j.cgh.2020.07.049
2. Izquierdo-Domínguez A, Valero AL, Mullol J. Comparative analysis of allergic rhinitis in children and adults. Curr Allergy Asthma Rep. 2013;13(2):142–51. 10.1007/s11882-012-0331-y
3. Asher MI, Montefort S, Björkstén B, Lai CKW, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–43. 10.1016/S0140-6736(06)69283-0
4. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy. 2005;60(3):350–3. 10.1111/j.1398-9995.2005.00751.x
5. Cardell L-O, Olsson P, Andersson M, Welin K-O, Svensson J, Tennvall GR, et al. TOTALL: high cost of allergic rhinitis-a national Swedish population-based questionnaire study. NPJ Prim Care Respir Med. 2016;26:15082. 10.1038/npjpcrm.2015.82
6. Testa D, Di Bari M, Nunziata M, Cristofaro GDE, Massaro G, Marcuccio G, et al. Allergic rhinitis and asthma assessment of risk factors in pediatric patients: A systematic review. Int J Pediatr Otorhinolaryngol. 2020;129:109759. 10.1016/j.ijporl.2019.109759
7. Asher MI, Stewart AW, Mallol J, Montefort S, Lai CKW, Aït-Khaled N, et al. Which population level environmental factors are associated with asthma, rhinoconjunctivitis and eczema? Review of the ecological analyses of ISAAC Phase One. Respir Res. 2010;11(1):8. 10.1186/1465-9921-11-8
8. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: Mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161(10):5733–44. 10.4049/jimmunol.161.10.5733
9. Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329(20):1468–75. 10.1056/NEJM199311113292007
10. Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF. Inflammatory bowel disease. Dtsch Arztebl Int. 2016;113(5):72–82. 10.3238/arztebl.2016.0072
11. Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053–60. 10.1001/jamapediatrics.2015.1982
12. Sicherer SH, Sampson HA. Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol. 2014;133(2):291–307. 10.1016/j.jaci.2013.11.020
13. Ko JK, Auyeung KK. Inflammatory bowel disease: Etiology, pathogenesis and current therapy. Curr Pharm Des. 2014;20(7):1082–96. 10.2174/13816128113199990416
14. Bernstein DI, Schwartz G, Bernstein JA. Allergic rhinitis: Mechanisms and treatment. Immunol Allergy Clin North Am. 2016;36(2):261–78. 10.1016/j.iac.2015.12.004
15. Turner D, Levine A, Escher JC, Griffiths AM, Russell RK, Dignass A, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–61. 10.1097/MPG.0b013e3182662233
16. Lee J W, Eun C S. Inflammatory bowel disease in Korea: Epidemiology and pathophysiology. Korean J Intern Med. 2022; 37(5):885–94. 10.3904/kjim.2022.138
17. Wasielewska Z, Dolinska A, Wilczynska D, Szaflarska-Poplawska A, Krogulska A. Prevalence of allergic diseases in children with inflammatory bowel disease. Postepy Dermatol Alergol. 2019;36(3):282–90. 10.5114/ada.2018.81189
18. Tzanakis NE, Tsiligianni IG, Siafakas NM. Pulmonary involvement and allergic disorders in inflammatory bowel disease. World J Gastroenterol. 2010;16(3):299–305. 10.3748/wjg.v16.i3.299
19. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol. 2006;12(30):4819–31. 10.3748/wjg.v12.i30.4819
20. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84. 10.7326/M14-2385
21. Wells G A, Wells G, Shea B, Shea B, O’Connell D, Peterson J, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, F, 2014 [C].
22. Alenezy N, Nugent Z, Herman S, Zaborniak K, Ramsey CD, Bernstein CN. Aeroallergen-related diseases predate the diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2023;29(7):1073–9. 10.1093/ibd/izac184
23. Card TR, Langan SM, Chu TP. Extra-gastrointestinal manifestations of inflammatory bowel disease may be less common than previously reported. Dig Dis Sci. 2016;61(9):2619–26. 10.1007/s10620-016-4195-1
24. Kappelman MD, Galanko JA, Porter CQ, Sandler RS. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child. 2011;96(11):1042–6. 10.1136/archdischild-2011-300633
25. Radon K, Windstetter D, Poluda AL, Mueller B, von Mutius E, Koletzko S. Contact with farm animals in early life and juvenile inflammatory bowel disease: A case-control study. Pediatrics. 2007;120(2):354–61. 10.1542/peds.2006-3624
26. Myrelid P, Dufmats M, Lilja I, Grinn C, Lannerstad O, Sjödahl R. Atopic manifestations are more common in patients with Crohn disease than in the general population. Scand J Gastroenterol. 2004;39(8):731–6. 10.1080/00365520410005955
27. D’Arienzo A, Manguso F, Scarpa R, Astarita C, D’Armiento FP, Bennato R, et al. Ulcerative colitis, seronegative spondyloarthropathies and allergic diseases: The search for a lin. Scand J Gastroenterol. 2002;37(10):1156–63. 10.1080/003655202760373362
28. D’Arienzo A, Manguso F, Astarita C, D’Armiento FP, Scarpa R, Gargano D, et al. Allergy and mucosal eosinophil infiltrate in ulcerative colitis. Scand J Gastroenterol. 2000;35(6):624–31. 10.1080/003655200750023598
29. Salem I, Ramser A, Isham N, Ghannoum MA. The gut microbiome as a major regulator of the gut-skin axis. Front Microbiol. 2018;9:1459. 10.3389/fmicb.2018.01459
30. Pugh SM, Rhodes J, Mayberry JF, Roberts DL, Heatley RV, Newcombe RG. Atopic disease in ulcerative colitis and Crohn’s disease. Clin Allergy. 1979;9(3):221–3. 10.1111/j.1365-2222.1979.tb01545.x
31. Jewell DP, Truelove SC. Reaginic hypersensitivity in ulcerative colitis. Gut. 1972;13(11):903–6. 10.1136/gut.13.11.903
32. Hammer B, Ashurst P, Naish J. Diseases associated with ulcerative colitis and Crohn’s disease. Gut. 1968;9(1):17–21. 10.1136/gut.9.1.17
33. Dixon LJ, Kabi A, Nickerson KP, McDonald C. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis. Inflamm Bowel Dis. 2015;21(4):912–22. 10.1097/MIB.0000000000000289
34. Guo AY, Stevens BW, Wilson RG, Russell CN, Cohen MA, Sturgeon HC, et al. Early life environment and natural history of inflammatory bowel diseases. BMC Gastroenterol. 2014;14:216. 10.1186/s12876-014-0216-8
35. Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J Gastroenterol Hepatol. 2010;25(2):325–33. 10.1111/j.1440-1746.2009.06140.x
36. Garn H, Bahn S, Baune BT, Binder EB, Bisgaard H, Chatila TA, et al. Current concepts in chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and inflammation. J Allergy Clin Immunol. 2016;138(1):47–56. 10.1016/j.jaci.2016.02.046
37. Li M, Wang M, Donovan SM. Early development of the gut microbiome and immune-mediated childhood disorders. Semin Reprod Med. 2014;32(1):74–86. 10.1055/s-0033-1361825
38. Nur Husna SM, Tan H-TT, Md Shukri N, Mohd Ashari NS, Wong KK. Nasal epithelial barrier integrity and tight junctions disruption in allergic rhinitis: Overview and pathogenic insights. Front Immunol. 2021;12:663626. 10.3389/fimmu.2021.663626
39. Zhang R, Zhang L, Li P, Pang K, Liu H, Tian L. Epithelial barrier in the nasal mucosa, related risk factors and diseases. Int Arch Allergy Immunol. 2023;184(5):481–501. 10.1159/000528969
40. Vancamelbeke M, Vermeire S. The intestinal barrier: A fundamental role in health and disease. Expert Rev Gastroenterol Hepatol. 2017;11(9):821–34. 10.1080/17474124.2017.1343143
41. Salvo Romero E, Alonso Cotoner C, Pardo Camacho C, Casado Bedmar M, Vicario M. The intestinal barrier function and its involvement in digestive disease. Rev Esp Enferm Dig. 2015;107(11):686–96. 10.17235/reed.2015.3846/2015
42. Barbara G, Barbaro MR, Fuschi D, Palombo M, Falangone F, Cremon C, et al. Inflammatory and microbiota-related regulation of the intestinal epithelial barrier. Front Nutr. 2021;8:718356. 10.3389/fnut.2021.718356
43. Vutcovici M, Brassard P, Bitton A. Inflammatory bowel disease and airway diseases. World J Gastroenterol. 2016;22(34):7735–41. 10.3748/wjg.v22.i34.7735
44. Einarsson R, Renck B, Taudorf E. In vitro studies of degradation of birch and timothy pollen allergen preparations by human duodenal juice. Allergy. 1988;43(6):469–72. 10.1111/j.1398-9995.1988.tb00921.x
45. Kabashima K, Honda T, Ginhoux F, Egawa G. The immunological anatomy of the skin. Nat Rev Immunol. 2019;19(1):19–30. 10.1038/s41577-018-0084-5
46. Sugita K, Kabashima K. Tight junctions in the development of asthma, chronic rhinosinusitis, atopic dermatitis, eosinophilic esophagitis, and inflammatory bowel diseases. J Leukoc Biol. 2020;107(5):749–62. 10.1002/JLB.5MR0120-230R
47. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2017;4(1):33–46. 10.1016/j.jcmgh.2017.03.007
48. Liu X, Tao J, Li J, Cao X, Li Y, Gao X, et al. Dysbiosis of fecal microbiota in allergic rhinitis patients. Am J Rhinol Allergy. 2020;34(5):650–60. 10.1177/1945892420920477
49. Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn’s disease and their unaffected relatives. Gut. 2011;60(5):631–7. 10.1136/gut.2010.223263
50. Pascal V, Pozuelo M, Borruel N, Casellas F, Campos D, Santiago A, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813–22. 10.1136/gutjnl-2016-313235
51. Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn’s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46(4):479–86. 10.1007/s00535-010-0368-4
52. Lee SY, Lee E, Park YM, Hong SJ. Microbiome in the gut–skin axis in atopic dermatitis. Allergy Asthma Immunol Res. 2018;10(4):354–62. 10.4168/aair.2018.10.4.354
53. Virta LJ, Ashorn M, Kolho KL. Cow’s milk allergy, asthma, and pediatric IBD. J Pediatr Gastroenterol Nutr. 2013;56(6):649–51. 10.1097/MPG.0b013e318285e9d8
54. Walker MM, Powell N, Talley NJ. Atopy and the gastrointestinal tract—A review of a common association in unexplained gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8(3):289–99. 10.1586/17474124.2014.881716
55. Kotlyar DS, Shum M, Hsieh J, Blonski W, Greenwald DA. Non-pulmonary allergic diseases and inflammatory bowel disease: A qualitative review. World J Gastroenterol. 2014;20(32):11023–32. 10.3748/wjg.v20.i32.11023
56. Hemdan NY, Birkenmeier G, Wichmann G, Abu El-Saad AM, Krieger T, Conrad K, et al. Interleukin-17-producing T helper cells in autoimmunity. Autoimmun Rev. 2010;9(11):785–92. 10.1016/j.autrev.2010.07.003
57. Ueno A, Jeffery L, Kobayashi T, Hibi T, Ghosh S, Jijon H. Th17 plasticity and its relevance to inflammatory bowel disease. J Autoimmun. 2018;87:38–49. 10.1016/j.jaut.2017.12.004
58. Liu Y, Zeng M, Liu Z. Th17 response and its regulation in inflammatory upper airway diseases. Clin Exp Allergy. 2015;45(3):602–12. 10.1111/cea.12378
59. Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: New immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut. 2009;58(8):1152–67. 10.1136/gut.2008.163667
60. Soh H, Lee HJ, Han K, Park S, Hong SW, Moon JM, et al. Atopic diseases are associated with development of inflammatory bowel diseases in Korea: A nationwide population-based study. Clin Gastroenterol Hepatol. 2021;19(10):2072–2081.e6. 10.1016/j.cgh.2020.07.049
Article Sidebar
Published
Nov 1, 2023
Article Details
How to Cite
Liu, J., Cai, L., Yang, R., Wei, L., Luo, H., & Gui, X. (2023). Risk of allergic rhinitis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Allergologia Et Immunopathologia, 51(6), 67-75. https://doi.org/10.15586/v51i6.943
Section
Review Article
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
Liu, J., Cai, L., Yang, R., Wei, L., Luo, H., & Gui, X. (2023). Risk of allergic rhinitis in patients with inflammatory bowel disease: A systematic review and meta-analysis. Allergologia Et Immunopathologia, 51(6), 67-75. https://doi.org/10.15586/v51i6.943